Mabion S.A.'s (WSE:MAB) Revenues Are Not Doing Enough For Some Investors
Apr 15
Have your own idea? Try our Stock Screener
Polish (WIG) Biotech Industry Analysis
UpdatedApr 15, 2025
DataAggregated Company Financials
Companies12
- 7D6.2%
- 3M6.1%
- 1Y-14.0%
- YTD3.6%
Over the last 7 days, the Biotech industry has risen 3.0%, driven by gains from Bioceltix of 15%. Meanwhile, Captor Therapeutics Spolka Akcyjna actually underperformed within the industry, shrinking 9.5% in the last week. In contrast, the industry has lost 15% in the last 12 months. Looking forward, earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the Polish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 15 Apr 2025 | zł2.0b | zł438.8m | -zł95,426,193.00 | 29.8x | -21x | 4.6x |
| Thu, 13 Mar 2025 | zł2.0b | zł438.6m | -zł94,885,631.00 | 30x | -21x | 4.5x |
| Sat, 08 Feb 2025 | zł2.0b | zł438.8m | -zł94,289,269.00 | 42.2x | -21.5x | 4.6x |
| Mon, 06 Jan 2025 | zł2.0b | zł408.7m | -zł84,434,269.00 | 41.3x | -23.1x | 4.8x |
| Wed, 04 Dec 2024 | zł1.9b | zł409.7m | -zł84,434,269.00 | 38.3x | -22.4x | 4.6x |
| Fri, 01 Nov 2024 | zł2.1b | zł409.6m | -zł91,994,969.00 | 62.4x | -23x | 5.2x |
| Sun, 29 Sep 2024 | zł2.1b | zł439.7m | -zł53,848,969.00 | 61.9x | -38.8x | 4.8x |
| Tue, 27 Aug 2024 | zł2.2b | zł445.0m | -zł63,393,784.00 | 65.5x | -34.5x | 4.9x |
| Thu, 25 Jul 2024 | zł2.2b | zł444.2m | -zł64,230,755.00 | 73.5x | -33.6x | 4.9x |
| Sat, 22 Jun 2024 | zł2.1b | zł444.3m | -zł95,946,755.00 | 71x | -21.7x | 4.7x |
| Mon, 20 May 2024 | zł2.3b | zł439.0m | -zł94,015,082.00 | 37.3x | -24.1x | 5.2x |
| Wed, 17 Apr 2024 | zł2.3b | zł437.8m | -zł72,667,007.00 | 52.5x | -31.4x | 5.2x |
| Fri, 15 Mar 2024 | zł2.3b | zł462.1m | -zł74,341,007.00 | 59.9x | -30.4x | 4.9x |
| Sun, 11 Feb 2024 | zł2.4b | zł459.9m | -zł74,255,671.00 | 123.7x | -31.9x | 5.1x |
| Tue, 09 Jan 2024 | zł2.8b | zł499.9m | -zł66,755,911.00 | 90.4x | -41.8x | 5.6x |
| Thu, 07 Dec 2023 | zł2.7b | zł499.9m | -zł66,755,911.00 | 92.2x | -39.7x | 5.3x |
| Sat, 04 Nov 2023 | zł2.7b | zł511.7m | -zł63,340,678.00 | 46x | -42.4x | 5.2x |
| Mon, 02 Oct 2023 | zł2.7b | zł518.4m | -zł60,858,678.00 | 48.5x | -44.4x | 5.2x |
| Wed, 30 Aug 2023 | zł2.8b | zł520.3m | -zł43,292,668.00 | 49.2x | -64.6x | 5.4x |
| Fri, 28 Jul 2023 | zł2.8b | zł520.7m | -zł42,515,291.00 | 53x | -67x | 5.5x |
| Sun, 25 Jun 2023 | zł2.9b | zł520.7m | -zł41,322,721.00 | 54.1x | -69.7x | 5.5x |
| Tue, 23 May 2023 | zł3.0b | zł520.8m | -zł43,534,021.00 | 69.3x | -67.9x | 5.7x |
| Thu, 20 Apr 2023 | zł2.9b | zł528.5m | -zł12,744,449.00 | 62.1x | -224x | 5.4x |
| Sat, 18 Mar 2023 | zł2.7b | zł488.6m | -zł16,165,349.00 | 59.9x | -168.3x | 5.6x |
| Mon, 13 Feb 2023 | zł2.9b | zł493.4m | -zł11,185,627.00 | 34.5x | -261.3x | 5.9x |
| Wed, 11 Jan 2023 | zł2.9b | zł496.5m | -zł10,783,764.00 | 48.6x | -269.2x | 5.8x |
| Fri, 09 Dec 2022 | zł2.7b | zł496.5m | -zł10,783,764.00 | 45.9x | -254.7x | 5.5x |
| Sun, 06 Nov 2022 | zł2.7b | zł444.0m | -zł13,473,868.00 | 57.4x | -197.3x | 6x |
| Tue, 04 Oct 2022 | zł2.5b | zł444.0m | -zł13,473,868.00 | 57.4x | -185.3x | 5.6x |
| Thu, 01 Sep 2022 | zł2.8b | zł390.2m | -zł7,043,258.00 | 60.9x | -399.4x | 7.2x |
| Sat, 30 Jul 2022 | zł2.7b | zł472.9m | zł66,686.00 | 27.7x | 40961.2x | 5.8x |
| Mon, 27 Jun 2022 | zł2.3b | zł472.9m | zł66,686.00 | 24.9x | 34687.6x | 4.9x |
| Wed, 25 May 2022 | zł2.5b | zł426.5m | zł14.0m | 35.2x | 176.6x | 5.8x |
| Fri, 22 Apr 2022 | zł2.8b | zł369.1m | -zł37,778,677.00 | 36.8x | -74.4x | 7.6x |
Price to Earnings Ratio
-74.4x
Current Industry PE
- Investors are pessimistic on the Polish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 4.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 5.9% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Polish Healthcare industry?
| PL Market | 6.77% | |
| Healthcare | 4.76% | |
| Biotech | 6.24% | |
| Biotech | 6.24% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BCX Bioceltix | zł113.40 | 18.4% +zł86.7m | 58.4% | PB13.5x | |
| MAB Mabion | zł10.46 | 12.7% +zł19.1m | -34.6% | PE16.5x | |
| SVE Synthaverse | zł4.47 | 3.5% +zł10.5m | 1.1% | PE70.7x | |
| PTG Poltreg | zł36.10 | 3.1% +zł5.1m | -35.8% | PS306.1x | |
| PUR Pure Biologics | zł10.57 | 8.3% +zł3.0m | 31.8% | PE-0.9x |
